Altre lingue Y-mAbs Therapeutics, Inc.

Azioni

YMAB

US9842411095

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
14,71 ^USD	-0,88%		-2,78%	+115,69%

14/03	Il direttore finanziario di Y-mAbs Therapeutics Bo Kruse si dimette	MT
14/03	Y-mAbs Therapeutics, Inc. annuncia le dimissioni di Bo Kruse da Vicepresidente esecutivo, Segretario e Tesoriere, con effetto dal 31 luglio 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024	26/04
Y-mAbs to Present at 2024 ASCO Annual Meeting	25/04
Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	14/03
Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	14/03
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer	14/03
Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer	14/03
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors	04/03
Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors	04/03
Y mAbs Therapeutics : mAbs Appoints Oncolog Executive Mar Tagliaferri, M.D. to its Board of Directors - Form 8-K	04/03
Y-mAbs Therapeutics Surges 18% in Premarket Activity Following Q4 Results; Reiterates Anticipated Cash Runway into 2027	01/03
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Reports Q4 Revenue $23.4M, vs. Street Est of $21M	29/02
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	29/02
Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	29/02
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	21/02
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024	16/02
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference	02/01
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)	22/12
Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) added to NASDAQ Biotechnology Index	18/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Y-mAbs Therapeutics, Inc.

Azioni

YMAB

US9842411095

Altre lingue

Filtri